Skip to main content

Drug Safety

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article

Mortality Risk in Rheumatoid Lung Patients

Jan 20, 2021

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.



Sparks

Read Article

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

MedPage Today
Jan 19, 2021

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment

Read Article
New QD Clinic—This week’s videos: Clinic Emergencies, Stopping Meds, 3 Issues After COVID Vaccination, My New Clinic COVID Routine, Raynaud's or Not https://t.co/R0zcRq6Sg1

Dr. John Cush RheumNow ( View Tweet)

Jan 18, 2021
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Dr. John Cush RheumNow ( View Tweet)
Jan 16, 2021

RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)

Jan 15, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...

Read Article
QD Clinic - Stopping Meds https://t.co/zhtAHLeGqT https://t.co/rFmCch4WJ4
Dr. John Cush RheumNow ( View Tweet)
Jan 15, 2021
Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis--Takeuchi et al has published their extensive experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
Dr. John Cush RheumNow ( View Tweet)
Jan 15, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ProDERM Study: IVIG in Dermatomyositis

Jan 13, 2021

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jan 13, 2021

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.



This oopen-label, observational, cohort study from 275 sites in Japan, included 1355 systemic lupus erythematosus (SLE) patients

Read Article

Hydroxychloroquine Shortage During COVID-19

Jan 12, 2021

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.



Despite public, political and quasi research evidence supporting

Read Article
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses.
Dr. John Cush RheumNow ( View Tweet)
Jan 12, 2021
SOBI announced Kineret is now FDA approved to treat DIRA (defic of IL-1 receptor antagonist), an ultra-rare, autoinflammatory Dz caused by a genetic mutation in the IL1RN gene,.

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2021
A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection.

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2021
Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%.

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2021
ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2021

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jan 08, 2021

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps
Dr. John Cush RheumNow ( View Tweet)
Jan 08, 2021
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. https://t.co/XwxkFz66fv https://t.co/E6W3H56jps
Dr. John Cush RheumNow ( View Tweet)
Jan 08, 2021

Adherence to Hydroxychloroquine Lowers Lupus Mortality

Jan 07, 2021

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025).

Dr. John Cush RheumNow ( View Tweet)

Jan 07, 2021

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jan 06, 2021

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine. A novel trial of IV rilonacept, an IL-1 α and IL-1β cytokine trap, resulted in rapid resolution of recurrent pericarditis and to a

Read Article

EULAR Guidance on Patient Adherence to Meds

Jan 06, 2021

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force to

Read Article
×